Posts

Showing posts from February, 2022

The outsourced cell therapy consumables market is projected to grow at an annualized rate of 18%, till 2031

  Roots Analysis has done a detailed study on Cell Therapy Consumables Market, 2021-2031 , covering key aspects of the industry’s evolution and identifying future growth opportunities.   To order this 230+ page report, which features 110+ figures and 120+ tables, please visit this – https://www.rootsanalysis.com/reports/cell-therapy-consumables-market/request-sample.html   Key Market Insights §   At present, more than 60 players worldwide claim to have the necessary expertise to offer a variety of materials for kit, media and reagent preparation, for a wide range of cell therapies §   The market landscape is geographically well distributed, with several players offering consumable products for research, as well as therapeutic purposes §   Over time, a number of stakeholders have established strong brand positions; in future, such companies are anticipated to contribute the most to the overall revenues generation potential §   In p...

Porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030.

  Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria   Roots Analysis has announced the addition of “ Porphyria Targeting Therapies Market, 2021-2030 ” report to its list of offerings.   Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibit...